A constraint has shaped biomedical research for decades: no individual researcher can fully read and contextualize the entire body of literature on a complex disease.

A scientist can become deeply knowledgeable and a lab can spend years building expertise around a specific pathway or target. But the volume of published research long ago outpaced what any human being could realistically absorb, compare, and connect, and it keeps growing. Comprehensive understanding stays partial, and the gap widens every year. 

This limitation has shaped science and discovery. It has influenced which diseases attracted funding, which hypotheses seemed worth pursuing on a career timeline, and which therapeutic areas pharmaceutical companies considered commercially viable. Rare diseases, neglected tropical conditions, diseases affecting small or poorly-funded patient populations have often lost out, held back by the manual labor of building a defensible research foundation across fragmented literature, inconsistent evidence, and experimental findings that don't map neatly onto one another.

The bottleneck has been cognitive capacity. Once AI begins to clear it, the question of which diseases a scientist can responsibly take on starts to change.

Researchers in early target discovery encounter this constantly. Even within a narrow therapeutic domain, evidence accumulates across animal models, cell studies, human trials, and contradictory experimental contexts that make direct comparison difficult. A finding from a mouse model may not translate to human biology. A study reporting strong results may have used a methodology that three other groups couldn't replicate. Important papers hide inside search results that traditional keyword queries never surface.

One of the more common errors comes from collapsing studies together that can't actually be compared. Reading five abstracts and drawing a general conclusion looks reasonable until you examine the methods and realize the contexts differ enough to make the comparison misleading. It happens because comparing methodologies across hundreds of studies manually takes time nobody has. Scientists adapted by narrowing their scope. They focused on tractable questions, worked in well-funded areas, avoided fields where the evidence was too fragmented or immature to justify the risk within a funding cycle. That narrowing was the only rational response to an impossible information environment. It makes less sense now.

Most of the AI conversation in biotech still revolves around productivity: faster searches, faster summaries, faster reporting. What AI is beginning to change is which research questions scientists can responsibly pursue in the first place. A researcher investigating a rare disease can now synthesize years of scattered literature in days. Smaller groups can now pursue hypotheses that once required dedicated teams just to establish foundational evidence.

This shows up in practice in ways that feel almost mundane until you sit with them. Ask a scientific question you've been thinking about for years, and get back not only the landmark papers everyone in your field already knows, but also contradictory findings you'd never encountered, adjacent research directions you hadn't considered, and obscure supporting evidence that would have taken weeks to uncover manually.

Scientific progress is path dependent, and that shapes everything that happens downstream. Researchers pursue the questions they can see, and entire therapeutic directions can remain unexplored simply because the supporting evidence never cohered clearly enough for anyone to justify the risk of pursuing them.

The case of rare disease research makes the point starkly. Small patient populations create funding problems from the start, while the supporting literature is often thin, scattered, or dispersed across adjacent fields nobody has connected. Building enough confidence to move from exploratory science into serious development work historically required enormous upfront intellectual labor before anyone could even determine whether a hypothesis was worth pursuing. A target assessment brief that might take a senior scientist weeks to assemble, pulling together animal model data, human evidence, off-target risk profiles, and contradictory findings, must be compelling enough to survive a portfolio prioritization meeting before more experiments get funded.

Yiannis Kiachopoulos, Causaly’s co-founder and CEO, looks at the same problem from the opposite end, at the level of how R&D organizations decide where to invest. For R&D organizations, he says the stakes reach beyond any one lab's workflow. “In immunology, deciding where to invest means making consequential decisions with an incomplete understanding of the biology,” he says. “AI can help teams examine more hypotheses, bring together evidence across diseases, and expose assumptions that need testing. That gives R&D organizations a stronger basis for deciding which scientific risks are worth taking."

What AI changes is how much exploratory work a scientist has to do before deciding whether a field is even worth pursuing seriously. The biology is as complicated as ever. Proteins still interact across systems in ways researchers only partially understand, a promising target can still create cascading downstream effects. What AI cuts is the time required to evaluate a field, and it lets a scientist weigh far more evidence than they could ever gather by hand. That changes how many fields a scientist can realistically take on, and how well they can judge each one. The consequences may be more profound than just simple productivity gains.

None of this works if scientists treat AI output as conclusions rather than material to interrogate. The most effective researchers describe the experience as extending their reach, with their own reasoning still the deciding layer.

The reproducibility problems that have damaged entire research programs didn't happen because scientists stopped caring about rigor. They happened in part because exhaustive scrutiny is time-prohibitive at scale. When a system can rapidly surface contradictory evidence, flag methodological differences across studies, and help a researcher stress-test a hypothesis before significant resources are committed, the odds of catching problems early improve. The scientist still has to scrutinize the evidence, and AI tools make thorough scrutiny realistic rather than aspirational.

Developing that critical relationship with AI output takes time. It's an instinct that has to be built, much like the skill of reading a paper critically, which takes years to develop. You learn what good synthesis looks like by seeing where it fails. The systems reward the same patience. They work best when you give them the context you’d give a new team member you were bringing up to speed, and that early investment pays back later. 

Biomedical research has historically concentrated around diseases large enough to justify the intellectual overhead required to study them properly. That concentration produced extraordinary advances and left large areas of human disease comparatively underexplored, which was a matter of arithmetic as much as attention.

Science is still hard and still uncertain. What changes is the cost of exploration, and once that cost shifts, the boundary of what becomes scientifically tractable moves with it. While funding research into these diseases is still a critical bottleneck, being able to consolidate information and justify the direction of study is an important step in pushing forward discoveries.

The diseases nobody could afford to study are starting to look like the diseases nobody can afford to miss studying.